Compare GLBS & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GLBS | XLO |
|---|---|---|
| Founded | 2006 | 2016 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.0M | 41.8M |
| IPO Year | 2007 | 2021 |
| Metric | GLBS | XLO |
|---|---|---|
| Price | $1.71 | $0.66 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $3.00 | $2.00 |
| AVG Volume (30 Days) | 363.8K | ★ 510.6K |
| Earning Date | 11-28-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $39,444,000.00 | $31,804,000.00 |
| Revenue This Year | $24.03 | $626.78 |
| Revenue Next Year | $13.92 | $79.08 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 18.49 | ★ 588.40 |
| 52 Week Low | $0.99 | $0.62 |
| 52 Week High | $1.99 | $1.70 |
| Indicator | GLBS | XLO |
|---|---|---|
| Relative Strength Index (RSI) | 62.89 | 39.03 |
| Support Level | $1.65 | $0.65 |
| Resistance Level | $1.78 | $0.68 |
| Average True Range (ATR) | 0.13 | 0.03 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 56.03 | 31.73 |
Globus Maritime Ltd is a dry bulk shipping company that provides marine transportation services internationally. The company owns, operates, and manages a fleet of dry bulk vessels that transport iron ore, coal, grain, steel products, cement, alumina, and other dry bulk cargo. Its operations are managed by its subsidiary which also provides in-house commercial and technical management for its vessels and also offers consulting services for an affiliated ship management company. It generates maximum revenues by charging customers for the use of vessels to transport dry bulk commodities.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.